Sulfacetamide-Prednisolone (sulfacetamide sodium/prednisolone sodium phosphate)

Dosage of sulfacetamide sodium is expressed in terms of the salt.

Dosage of fixed-combination preparations containing sulfacetamide sodium and prednisolone acetate or prednisolone sodium phosphate are expressed in terms of the salts.

Potency of some sodium phosphate preparations is expressed in terms of prednisolone phosphate.

For use in the eye, 1 or 2 drops of prednisolone acetate ophthalmic suspension or prednisolone sodium phosphate ophthalmic solution may be instilled into the conjunctival sac every hour during the day and every 2 hours during the night for initial therapy in severe cases. In mild or moderate inflammation or when a favorable response is attained in severe cases, dosage may be reduced to 1 or 2 drops every 3-12 hours.

Alternatively, prednisolone sodium phosphate ophthalmic ointment may be instilled into the conjunctival sac 3 or 4 times daily initially, and once or twice daily thereafter. The ointment also may be used at night in conjunction with daytime use of a suspension or solution to reduce the frequent applications required with the liquid dosage forms.

The lowest effective concentration should be used and, if improvement does not occur within several days, the drug should be discontinued and other therapy begun. The duration of treatment depends on the type and severity of the disease and may range from a few days to several weeks; long-term therapy should be avoided. When the drug is discontinued, dosage should be gradually tapered to avoid exacerbation of the disease.

Prednisolone acetate or sodium phosphate is applied topically to the eye. Care should be taken to avoid contamination of the tip of the ointment tube or dropper when the drug is used ophthalmically.

No dosing information is available for this tab.

No dosing information is available for this tab.

Sulfacetamide sodium is incompatible with preparations containing silver. (See Chemistry and Stability: Stability)

Because the antibacterial activity of sulfonamides involves competitive inhibition of p-aminobenzoic acid (PABA), antagonism may occur between sulfonamides and local anesthetics that are PABA derivatives.

There are no contraindication interactions for this drug.

There are no severe interactions for this drug.

There are no moderate interactions for this drug.

There is no enhanced messaging for this drug.

There are no contraindication contraindications for this drug.

There are no severe contraindications for this drug.

There are no moderate contraindications for this drug.

There is no enhanced messaging for this drug.

There are no severe adverse reactions for this drug.

There are no less severe adverse reactions for this drug.

No enhanced messaging available.

No enhanced messaging available.

Animal reproduction studies have not been performed using sulfacetamide ophthalmic preparations.

There are no adequate and well-controlled studies using sulfonamide ophthalmic preparations in pregnant women, and it is not known whether topically applied sulfonamides can cause fetal harm when administered to pregnant women. Use of oral sulfonamides in pregnant women at term may result in kernicterus in neonates.

Sulfacetamide sodium ophthalmic preparations, including fixed-combination preparations containing sulfacetamide sodium and a corticosteroid, should be used during pregnancy only if potential benefits justify potential risks to the fetus.

Systemically administered sulfonamides are capable of producing kernicterus in breast-fed infants.

Because of the potential for development of kernicterus in neonates, a decision should be made whether to discontinue nursing or discontinue the drug taking into account the importance of the drug to the woman.

No enhanced messaging available.